Stocks / NASDAQ / Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc.

Our Opinion

Stemline Therapeutics is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.

“SL-801 has demonstrated preclinical anti-cancer activity, including efficacy and safety in animal models, across a wide array of solid and hematologic cancers.” Read the following article

Company Description

Stemline Therapeutics, Inc., incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present in a range of hematologic cancers.
[Source: Reuters]

Company Website: